Kodikaz Therapeutic Solutions Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3M

  • Investors
  • 8

Kodikaz Therapeutic Solutions General Information

Description

Operator of a genomic transfer delivery platform designed for both RNA and DNA delivery vectors. The company translates previously unknown cell-recognition and genomic integration mechanisms through the discovery of technologies derived from findings in human cancers and also generates both in vitro and in vivo data in oncology, including pancreatic, myeloma, and colorectal cancers, enabling clients to develop cell-specific gene transfer technologies into curative therapies.

Contact Information

Website
www.kodikaz.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 180 Varick Street
  • 6th Floor
  • New York, NY 10014
  • United States
+1 (716)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 180 Varick Street
  • 6th Floor
  • New York, NY 10014
  • United States
+1 (716)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kodikaz Therapeutic Solutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 21-May-2024 $3M Completed Pre-Clinical Trials
1. Grant 15-Aug-2021 Completed Pre-Clinical Trials
To view Kodikaz Therapeutic Solutions’s complete valuation and funding history, request access »

Kodikaz Therapeutic Solutions Patents

Kodikaz Therapeutic Solutions Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4590309-A2 Nucleic acid-based delivery systems and uses thereof Pending 29-Jul-2022
WO-2024026466-A2 Nucleic acid-based delivery systems and uses thereof Inactive 29-Jul-2022
WO-2024026466-A3 Nucleic acid-based delivery systems and uses thereof Inactive 29-Jul-2022
CA-3239944-A1 Receptor-mediated delivery of nucleic acids Pending 07-Dec-2021
EP-4444880-A1 Receptor-mediated delivery of nucleic acids Pending 07-Dec-2021 C07K16/2833
To view Kodikaz Therapeutic Solutions’s complete patent history, request access »

Kodikaz Therapeutic Solutions Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kodikaz Therapeutic Solutions Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Real Estate Equities Real Estate
AmorChem Venture Capital Minority
Epidarex Capital Venture Capital Minority
Georgia Research Alliance Not-For-Profit Venture Capital
GRA Venture Fund Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Kodikaz Therapeutic Solutions FAQs

  • When was Kodikaz Therapeutic Solutions founded?

    Kodikaz Therapeutic Solutions was founded in 2018.

  • Where is Kodikaz Therapeutic Solutions headquartered?

    Kodikaz Therapeutic Solutions is headquartered in New York, NY.

  • What is the size of Kodikaz Therapeutic Solutions?

    Kodikaz Therapeutic Solutions has 8 total employees.

  • What industry is Kodikaz Therapeutic Solutions in?

    Kodikaz Therapeutic Solutions’s primary industry is Drug Discovery.

  • Is Kodikaz Therapeutic Solutions a private or public company?

    Kodikaz Therapeutic Solutions is a Private company.

  • What is Kodikaz Therapeutic Solutions’s current revenue?

    The current revenue for Kodikaz Therapeutic Solutions is .

  • How much funding has Kodikaz Therapeutic Solutions raised over time?

    Kodikaz Therapeutic Solutions has raised $3M.

  • Who are Kodikaz Therapeutic Solutions’s investors?

    Alexandria Real Estate Equities, AmorChem, Epidarex Capital, Georgia Research Alliance, and GRA Venture Fund are 5 of 8 investors who have invested in Kodikaz Therapeutic Solutions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process